CTOs on the Move

HMA Inc

www.hma-inc.com

 
HMA Inc is a Tempe, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.hma-inc.com
  • 1600 W Broadway Rd Ste 300
    Tempe, AZ USA 85282
  • Phone: 480.921.8944

Executives

Name Title Contact Details

Similar Companies

Neuwave

NeuWave Medical specializes in developing and commercializing energy-based minimally invasive medical devices. These devices must deliver improved healthcare economics and a better experience for patients in terms of outcomes or quality of life. NeuWave Medical, Inc. is a spin-off company from the University of Wisconsin - Madison. NeuWave arose as the result of an academic collaboration between engineers and physicians who wished to improve their ability to treat cancer and other important clinical problems. As a result, NeuWave is highly focused on solving real clinical problems in a manner that will directly benefit patients by being more effective, minimally invasive, and cost conscious.

Most Products Inc

Most Products Inc is a Plainwell, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caliva

Free same-day delivery. Hundreds of cannabis items. Shop edibles, flower, lotions and tinctures from dozens of brands, including Caliva’s own carefully cultivated products.

Criterium

Criterium is a Saratoga Springs, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biological Dynamics

Biological Dynamics Inc. is an early stage company that has developed a proprietary AC Electrokinetic technology to rapidly extract nanoparticles in high-conductance physiological solutions. Biological Dynamics was founded in 2008 by Raj Krishnan and David Charlot, Bioengineering PHD graduates from the University of California, San Diego (UCSD). Our vision is to enable healthcare practitioners to detect, diagnose and monitor cancer and other diseases from a simple blood draw (or other bodily fluid) and rapidly intervene, increasing patient survivability while driving down the total burden costs.